Clinical trials: Retinal Vein Occlusion (RVO)
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Macular Edema, Retinal Vein Occlusion
DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone (DDS-25) for the treatment of macular edema associated with retinal vein occlusion.
- Trial name
- DDS-25 (NCT01662518)
- Testing
- Dexamethasone drug delivery system (DDS-25)
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- Centro de Pesquisa Rubens Siqueira
Retinal Vein Occlusion, Macula Edema
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
- Trial name
- NCT03093701
- Testing
- TLC399 (ProDex)
- Where
- 20 sites in United States
- Volunteers
- 31 people
- Sponsor
- Taiwan Liposome Company
Macular Edema, Retinal Vein Occlusion
Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)
The purpose of this study is to evaluate the effects of intravitreal Lucentis® (Ranibizumab) and investigate the anatomical and functional improvement following this treatment in patients with macular edema due to retinal vein…
- Trial name
- NCT00942864
- Testing
- ranibizumab
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Novartis Korea Ltd.
Retinal Vein Occlusion, Diabetic Macular Edema
Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
This interventional study will evaluate the retinal vascular dynamics associated with Intravitreal Aflibercept Injection (IAI) therapy in eyes with diabetic macular edema (DME) or macular edema secondary to retinal vein occlusion…
- Conditions
- Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
- Trial name
- PERMEATE (NCT02503540)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Justis Ehlers
Macular Degeneration, Diabetic Retinopathy
Patient Comfort Following Intravitreal Injections Using Iheezo Versus Standard Anesthesia
Prospective comparative clinical study. One hundred eyes of 50 patients were included. All patients received bilateral same-day intravitreal injections, with Iheezo administered to only one randomly selected eye and standard…
- Conditions
- Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion (RVO)
- Trial name
- NCT07779356
- Testing
- Iheezo, Lidocaine pledget
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Retina Consultants of Delmarva
Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients
Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body, such as the eyes, kidneys…
- Conditions
- Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation
- Trial name
- NCT06879301
- Testing
- Intravitreal injection of aflibercept 8 mg
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tanta University
Retinal Vein Occlusion (RVO)
Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
Retinal vein occlusion (RVO), a common retinal vascular disease, is frequently treated with anti-vascular endothelial growth factor (anti-VEGF) agents as first-line therapy.
- Trial name
- NCT07133438
- Testing
- Anti-VEGF drug, Mecobalamin 5 MG
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Age-Related Macular Degeneration, Diabetic Macular Edema
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
The goal of this clinical trial is to learn if drug Faricimab works to treat nAMD, DME or RVO in adults. It will also learn about the safety of drug Faricimab.
- Conditions
- Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT06572553
- Testing
- Faricimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine